These include the combination of BRAF inhibitors with MEK inhibitors to block multiple signaling pathways, the use of EGFR inhibitors in combination with BRAF inhibitors, and the combination of targeted therapies with immunotherapy to enhance the immune response against tumor cells. Here, EGFR is linked to neoplasm.